** Shares of Chinese biopharmaceutical group Zai Lab Ltd
9688.HK jump as much as 11% to HK$17.98, their highest since
Feb. 2, and on course for fourth consecutive session of gains
** Zai Lab says China's National Medical Products
Administration NMPA has approved the New Drug Application for
its AUGTYROTM, or repotrectinib, for treatment of adult patients
with metastatic ROS1-positive non-small-cell lung cancer
** Company says it has an exclusive license agreement with
Turning Point Therapeutics Inc - a unit of Bristol Myers Squibb
BMY.N , to develop and commercialize repotrectinib in mainland
China, Hong Kong, Macau and Taiwan
** Hong Kong's healthcare index .HSCIH slips 0.7%, while
Hang Seng Composite Index .HSCI climbs 0.7% and Hang Seng
Index .HSI adds 0.5%
** Zai Lab stock down 23.8% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))